financetom
Business
financetom
/
Business
/
Rocket Doctor AI in Q2 Produces First "Significant" Quarterly Revenue
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Rocket Doctor AI in Q2 Produces First "Significant" Quarterly Revenue
Aug 29, 2025 6:34 AM

09:27 AM EDT, 08/29/2025 (MT Newswires) -- Rocket Doctor AI ( TREIF ) on Friday reported its first "significant" revenue producing quarter as its net loss narrowed.

For the three-months ended June 30, the net comprehensive loss declined to $2.68 million or $0.04 per share, compared with $2.72 million or $0.07 per share, a year earlier.

Revenue for the quarter increased to $0.5 million, compared with $nil in Q2 2024, primarily due to acquisition growth with the Rocket Doctor buy.

"Management believes the Company enters the second half of 2025 with a stronger foundation, driven by its shift to an enterprise-focused model, the integration of Rocket Doctor Inc., and the continued expansion of the Global Library of Medicine (GLM)," said the company in a statement.

Shares of the company closed down 10% to $0.62 on Thursday on the Canadian Securities Exchange.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Exco Technologies Reports a Lower Fiscal Fourth-Quarter Profit as Sales Drop
Exco Technologies Reports a Lower Fiscal Fourth-Quarter Profit as Sales Drop
Nov 27, 2024
05:28 PM EST, 11/27/2024 (MT Newswires) -- Exco Technologies ( EXCOF ) after trade Wednesday said its fiscal fourth-quarter profit fell on weaker sales. The auto parts and casting company said it earned $7.7 million, or $0.20 per share, down from $9.2 million, or $0.24, in the same quarter last year. Sales for the quarter ended Sept. 30 fell 3%...
Alnylam Pharmaceuticals Insider Sold Shares Worth $422,144, According to a Recent SEC Filing
Alnylam Pharmaceuticals Insider Sold Shares Worth $422,144, According to a Recent SEC Filing
Nov 27, 2024
05:29 PM EST, 11/27/2024 (MT Newswires) -- Pushkal Garg, CMO & EVP Dev & Med Affairs, on Nov. 25 and Nov. 26, sold 1,682 shares in Alnylam Pharmaceuticals ( ALNY ) for $422,144. Following the Form 4 filing with the SEC, Garg has control over a total of 18,138 shares of the company, with 17,457 shares held directly and 681...
Nerdy Insider Bought Shares Worth $432,000, According to a Recent SEC Filing
Nerdy Insider Bought Shares Worth $432,000, According to a Recent SEC Filing
Nov 27, 2024
05:23 PM EST, 11/27/2024 (MT Newswires) -- Charles K. Cohn, 10% Owner, Director, Chief Executive Officer, on Nov. 25, executed a purchase for 300,000 shares in Nerdy ( NRDY ) for $432,000. Following the Form 4 filing with the SEC, Cohn has control over a total of 48,388,009 shares of the company, with 9,258,298 shares held directly and 39,129,711 controlled...
Alnylam Pharmaceuticals Insider Sold Shares Worth $1,309,853, According to a Recent SEC Filing
Alnylam Pharmaceuticals Insider Sold Shares Worth $1,309,853, According to a Recent SEC Filing
Nov 27, 2024
05:29 PM EST, 11/27/2024 (MT Newswires) -- Yvonne Greenstreet, Director, Chief Executive Officer, on Nov. 25 and Nov. 26, sold 5,219 shares in Alnylam Pharmaceuticals ( ALNY ) for $1,309,853. Following the Form 4 filing with the SEC, Greenstreet has control over a total of 79,287 shares of the company, with 78,880 shares held directly and 407 controlled indirectly. SEC...
Copyright 2023-2025 - www.financetom.com All Rights Reserved